Literature DB >> 11867732

Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity.

Darja Schmidt1, Stefan Müller.   

Abstract

The activity of the p53 tumor suppressor protein and the c-Jun protooncogene is regulated by posttranslational modifications, such as phosphorylation or ubiquitination. In addition, covalent attachment of the ubiquitin-like modifier SUMO appears to modulate their transcriptional activity. Sumoylation proceeds via an enzymatic pathway that is mechanistically analogous to ubiquitination, but requires a different E1-activating enzyme and Ubc9, a SUMO-specific E2-conjugating enzyme. Here, we show that two members of the PIAS family, PIAS1 and PIASxbeta, act as specific E3-like ligases that promote sumoylation of p53 and c-Jun in vitro and in vivo. The PIAS proteins physically interact with both p53 and c-Jun. In addition, they bind to Ubc9, suggesting that they recruit the E2 enzyme to their respective substrate. The SUMO ligase activity requires the conserved zinc-finger domain, which is distantly related to the essential RING-finger motif, found in a subset of ubiquitin ligases. Furthermore, similar to RING-type ubiquitin ligases, PIASxbeta can catalyze its own modification. Hence, these data further extend the analogy between the ubiquitin and SUMO pathway. Strikingly, PIAS proteins strongly repress the transcriptional activity of p53, suggesting that the PIAS-SUMO pathway plays a crucial role in the regulation of p53 and presumably other transcription factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867732      PMCID: PMC122440          DOI: 10.1073/pnas.052559499

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  SUMO-1 modification activates the transcriptional response of p53.

Authors:  M S Rodriguez; J M Desterro; S Lain; C A Midgley; D P Lane; R T Hay
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

2.  MBP1: a novel mutant p53-specific protein partner with oncogenic properties.

Authors:  W M Gallagher; M Argentini; V Sierra; L Bracco; L Debussche; E Conseiller
Journal:  Oncogene       Date:  1999-06-17       Impact factor: 9.867

Review 3.  Modulation of STAT signaling by STAT-interacting proteins.

Authors:  K Shuai
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 4.  SUMO--nonclassical ubiquitin.

Authors:  F Melchior
Journal:  Annu Rev Cell Dev Biol       Date:  2000       Impact factor: 13.827

Review 5.  Ubiquitin and its kin: how close are the family ties?

Authors:  S Jentsch; G Pyrowolakis
Journal:  Trends Cell Biol       Date:  2000-08       Impact factor: 20.808

Review 6.  RING finger proteins: mediators of ubiquitin ligase activity.

Authors:  C A Joazeiro; A M Weissman
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

7.  c-Jun and p53 activity is modulated by SUMO-1 modification.

Authors:  S Muller; M Berger; F Lehembre; J S Seeler; Y Haupt; A Dejean
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

8.  Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells.

Authors:  A Junicho; T Matsuda; T Yamamoto; H Kishi; K Korkmaz; F Saatcioglu; H Fuse; A Muraguchi
Journal:  Biochem Biophys Res Commun       Date:  2000-11-11       Impact factor: 3.575

9.  The zinc finger protein Gfi-1 can enhance STAT3 signaling by interacting with the STAT3 inhibitor PIAS3.

Authors:  B Rödel; K Tavassoli; H Karsunky; T Schmidt; M Bachmann; F Schaper; P Heinrich; K Shuai; H P Elsässer; T Möröy
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

10.  Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif.

Authors:  A Minty; X Dumont; M Kaghad; D Caput
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

View more
  146 in total

Review 1.  Modification with SUMO. A role in transcriptional regulation.

Authors:  Alexis Verger; José Perdomo; Merlin Crossley
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

2.  Functional mimicry of the acetylated C-terminal tail of p53 by a SUMO-1 acetylated domain, SAD.

Authors:  Amrita Cheema; Chad D Knights; Mahadev Rao; Jason Catania; Ricardo Perez; Brigitte Simons; Sivanesan Dakshanamurthy; Vamsi K Kolukula; Maddalena Tilli; Priscilla A Furth; Christopher Albanese; Maria Laura Avantaggiati
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Authors:  Andrea Rabellino; Brandon Carter; Georgia Konstantinidou; Shwu-Yuan Wu; Alessandro Rimessi; Lauren A Byers; John V Heymach; Luc Girard; Cheng-Ming Chiang; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

4.  EBNA3C coactivation with EBNA2 requires a SUMO homology domain.

Authors:  Adam Rosendorff; Diego Illanes; Gregory David; Jeffrey Lin; Elliott Kieff; Eric Johannsen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression.

Authors:  Gergana Dobreva; Julia Dambacher; Rudolf Grosschedl
Journal:  Genes Dev       Date:  2003-12-15       Impact factor: 11.361

Review 6.  Posttranslational modification of p53: cooperative integrators of function.

Authors:  David W Meek; Carl W Anderson
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

7.  Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis.

Authors:  Stergios J Moschos; Yin-Yuan Mo
Journal:  J Mol Histol       Date:  2006-06-07       Impact factor: 2.611

8.  cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation.

Authors:  Rosanna Lau; Min Ying Niu; M A Christine Pratt
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

9.  Physical and functional interactions of histone deacetylase 3 with TFII-I family proteins and PIASxbeta.

Authors:  María Isabel Tussié-Luna; Dashzeveg Bayarsaihan; Edward Seto; Frank H Ruddle; Ananda L Roy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-18       Impact factor: 11.205

10.  PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73.

Authors:  Eliana Munarriz; Daniela Barcaroli; Anastasis Stephanou; Paul A Townsend; Carine Maisse; Alessandro Terrinoni; Michael H Neale; Seamus J Martin; David S Latchman; Richard A Knight; Gerry Melino; Vincenzo De Laurenzi
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.